Neuroimmunology Reports最新文献_第5页

Effectiveness of Methylprednisolone against COVID-19–related Guillain–Barré Syndrome: A Single Case Report 甲基强的松龙对 COVID-19 相关格林-巴利综合征的疗效：单个病例报告

Neuroimmunology Reports Pub Date : 2024-01-01 DOI: 10.1016/j.nerep.2024.100212

Azusa Sunouchi , Ryota Amano , Ayumi Uchibori

{"title":"Effectiveness of Methylprednisolone against COVID-19–related Guillain–Barré Syndrome: A Single Case Report","authors":"Azusa Sunouchi , Ryota Amano , Ayumi Uchibori","doi":"10.1016/j.nerep.2024.100212","DOIUrl":"https://doi.org/10.1016/j.nerep.2024.100212","url":null,"abstract":"<div><h3>Background</h3><p>The first-line treatment for GBS is plasma exchange or intravenous immunoglobulin. In contrast, corticosteroids are not recommended for treating GBS. However, COVID-19–related Guillain–Barré syndrome occurs via mechanisms different from other infectious diseases.</p></div><div><h3>Case report</h3><p>A 63-year-old woman experienced back pain following COVID-19, progressing to numbness/weakness of the extremities, left peripheral facial nerve palsy, and abnormal sensation/allodynia in the face and extremities. Compound muscle action potentials showed severe temporal dispersion. Intravenous immunoglobulin administration slightly improved the lower limb muscle weakness and facial nerve palsy but was ineffective for the pain in the chest and back and numbness of the extremities. Three courses of intravenous methylprednisolone (IVMP) enabled the patient to walk unassisted.</p></div><div><h3>Conclusions</h3><p>This case is the first to demonstrate IVMP's effectiveness against COVID-19–related Guillain–Barré syndrome. Further studies are required to establish treatments for COVID-19–related Guillain–Barré syndrome.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"5 ","pages":"Article 100212"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667257X24000135/pdfft?md5=094fb0abd491cd217cd599c2d132a874&pid=1-s2.0-S2667257X24000135-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140823878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A fulminant neuromyelitis optica spectrum disorder (NMOSD) Presenting with continued area postrema syndrome after COVID-19 infection: a case report 一例感染 COVID-19 后出现持续区域后遗综合征的暴发性神经脊髓炎视网膜频谱紊乱症 (NMOSD)：病例报告

Neuroimmunology Reports Pub Date : 2024-01-01 DOI: 10.1016/j.nerep.2024.100215

Yu Chen , Sen-Kuang Hou , Ruei-Yi Tai , Wen-Yu Yu , Sheng-Feng Lin

{"title":"A fulminant neuromyelitis optica spectrum disorder (NMOSD) Presenting with continued area postrema syndrome after COVID-19 infection: a case report","authors":"Yu Chen , Sen-Kuang Hou , Ruei-Yi Tai , Wen-Yu Yu , Sheng-Feng Lin","doi":"10.1016/j.nerep.2024.100215","DOIUrl":"10.1016/j.nerep.2024.100215","url":null,"abstract":"<div><p>Area postrema syndrome, characterized by unexplained intractable nausea, frequent vomiting, and hiccups, serves as a hallmark feature of neuromyelitis optica spectrum disorder (NMOSD), often indicative of brain involvement. We report a case of a 26-year-old woman who, following recovery from a recent COVID-19 infection, endured persistent nausea and vomiting for 10 days. Subsequently, she presented to the emergency department with acute bilateral lower limb weakness and urinary retention. Brain magnetic resonance imaging (MRI) revealed hyperintense lesions in the area postrema on T2-weighted imaging, while spinal cord MRI demonstrated long-segment hyperintense lesions from the C2 to T12 levels on T2-weighted imaging. Cerebrospinal fluid analysis showed pleocytosis and elevated protein levels, alongside the presence of positive AQP-4 antibodies in the serum, confirming the diagnosis of NMOSD. Treatment comprising plasma exchange, pulse steroid therapy, and subsequent intravenous immunoglobulin administration led to notable improvement in bladder control and muscle strength. Our case underscores the significance of recognizing area postrema involvement, even in patients with post-COVID-19 symptoms, and highlights the necessity for vigilance in diagnosing NMOSD, particularly when initial symptoms mimic gastrointestinal discomfort.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"5 ","pages":"Article 100215"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667257X24000160/pdfft?md5=8843a4119dd91703b8210a1d04439105&pid=1-s2.0-S2667257X24000160-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141279196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum to “New onset myoclonus and encephalopathy in a woman with multiple sclerosis: Consider the medications” [Neuroimmunology Reports Volume 1, December 2021, 100020] 多发性硬化症女性患者新发肌阵挛和脑病：考虑药物"[《神经免疫学报告》第1卷，2021年12月，100020]

Neuroimmunology Reports Pub Date : 2024-01-01 DOI: 10.1016/j.nerep.2024.100204

Sonam Dilwali , Emmanuelle Waubant , Kristen M. Krysko

引用次数: 0

Efficacy of eculizumab in acute refractory pediatric neuromyelitis optica: A case report 依库珠单抗对急性难治性小儿神经脊髓炎视网膜病变的疗效：病例报告

Neuroimmunology Reports Pub Date : 2024-01-01 DOI: 10.1016/j.nerep.2024.100213

Michael Enriquez , Scott Rosenthal , Loren A. McLendon , Jeffrey L. Bennett , Amanda L. Piquet , Ryan Kammeyer

引用次数: 0

Change from platform to high efficacy disease-modifying treatment for multiple sclerosis despite NEDA 尽管有 NEDA，多发性硬化症患者仍可从平台治疗转为高效疾病修饰治疗

Neuroimmunology Reports Pub Date : 2024-01-01 DOI: 10.1016/j.nerep.2024.100211

Yavor Yalachkov , Katja Akgün , Tjalf Ziemssen

引用次数: 0

Interferon-beta-1a induced retinopathy in a 14-year-old female patient with multiple sclerosis 一名 14 岁女性多发性硬化症患者因干扰素-β-1a 引起的视网膜病变

Neuroimmunology Reports Pub Date : 2024-01-01 DOI: 10.1016/j.nerep.2024.100202

C. Tsimakidi, M. Gontika, D. Gkougka, K Rizonaki, S. Fanouraki, C. Kotsalis

引用次数: 0

Multiple sclerosis and optic neuritis triggered by COVID-19 mRNA 由 COVID-19 mRNA 引发的多发性硬化症和视神经炎

Neuroimmunology Reports Pub Date : 2024-01-01 DOI: 10.1016/j.nerep.2023.100198

Giovanna Thais Torques Moretti , Giorgio Fabiani , Georgette Mouchaileh Evangelista Ferreira , Jessica Pizatto de Araujo , Eduardo Hummelgen

{"title":"Multiple sclerosis and optic neuritis triggered by COVID-19 mRNA","authors":"Giovanna Thais Torques Moretti , Giorgio Fabiani , Georgette Mouchaileh Evangelista Ferreira , Jessica Pizatto de Araujo , Eduardo Hummelgen","doi":"10.1016/j.nerep.2023.100198","DOIUrl":"https://doi.org/10.1016/j.nerep.2023.100198","url":null,"abstract":"<div><h3>Background</h3><p>In December 2019, the World Health Organization declared COVID-19 a pandemic; an unprecedented health crisis has rocked the world. Enormous efforts by governments, the pharmaceutical industry, and health professionals, including a new mRNA vaccine technology against SARS-CoV-2, have been massively employed to control the COVID-19 pandemic. The vaccine's primary mechanism is based on S glycoprotein, the leading viral surface antigen, which induces protective neutralizing antibodies.</p></div><div><h3>Case presentation</h3><p>This project aims to present two cases of demyelinating syndromes in previously asymptomatic patients. The triggering factor in both cases was vaccination against COVID-19 with mRNA vaccines.</p></div><div><h3>Case Report</h3><p>The first case is a young female, 25 years old, previously asymptomatic, one week after the ChAdOx1 Vaccine developed right hemiparesis. Brain MRI and MRI of the spinal cord demonstrated multiple hyperintense lesions, acute and chronic. The second case is an 8-year-old Caucasian male; 12 days after the double dose of the Pfizer-BioNTech vaccine, the patient complained of bilateral visual blurring. The patient was pulsed with methylprednisolone one g/day/5 days with complete recovery.</p></div><div><h3>Conclusion</h3><p>Rarely can vaccines trigger multiple sclerosis or optic neuritis. This report demonstrated two demyelinating syndromes triggered by the m-RNA COVID-19 vaccine.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"5 ","pages":"Article 100198"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667257X23000360/pdfft?md5=1e126c4ed0de1246d9be568a068d877f&pid=1-s2.0-S2667257X23000360-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139111690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transitory recurrent diplopia and dysarthria with MRI mimicking central pontine myelinolysis: a peculiar NMOSD onset 短暂性复发性复视和构音障碍，核磁共振成像模拟中枢神经髓鞘溶解：一种特殊的 NMOSD 发病情况

Neuroimmunology Reports Pub Date : 2024-01-01 DOI: 10.1016/j.nerep.2024.100207

C. Chiavazza , E. Genovese , M. Narracci , S. Gasverde , C. Baima , D.M. Papurello

引用次数: 0

Allopurinol treatment in pediatric multiple sclerosis 别嘌醇治疗小儿多发性硬化症

Neuroimmunology Reports Pub Date : 2024-01-01 DOI: 10.1016/j.nerep.2024.100209

Yousef A Assaleh , Farah Thabet , Kalthoum Graies-Tlili , Brahim Tabarki

引用次数: 0

Chronic inflammatory demyelinating polyneuropathy or subacute Guillain-Barré syndrome? Not always an easy differential diagnosis 慢性炎症性脱髓鞘多发性神经病还是亚急性格林-巴利综合征？鉴别诊断并非易事

Neuroimmunology Reports Pub Date : 2024-01-01 DOI: 10.1016/j.nerep.2023.100196

Elisabetta Cecconi , Sara Torricelli , Gabriele Rosario Rodolico , Martina Sperti , Maddalena Spalletti , Roberto Fratangelo , Valentina Bessi , Leonello Guidi , Sabrina Matà

{"title":"Chronic inflammatory demyelinating polyneuropathy or subacute Guillain-Barré syndrome? Not always an easy differential diagnosis","authors":"Elisabetta Cecconi , Sara Torricelli , Gabriele Rosario Rodolico , Martina Sperti , Maddalena Spalletti , Roberto Fratangelo , Valentina Bessi , Leonello Guidi , Sabrina Matà","doi":"10.1016/j.nerep.2023.100196","DOIUrl":"https://doi.org/10.1016/j.nerep.2023.100196","url":null,"abstract":"<div><p>Guillain-Barré syndrome (GBS) is an immuno-mediated disorder of the peripheral nervous system with an acute onset of 2–4 weeks, and a monophasic course. In the subacute variant the symtpoms nadir is reached in 4–8 weeks. However, in sporadic cases the onset and the evolution of the disease may be different than expected, leading to significant diagnostic difficulties.</p><p>Case report: A 78-yrs old man presented at our Hospital with a 4-month history of progressive, diffuse motor and sensory deficit. He had previously undergone two electrophysiological examinations with uncertain findings. At hospitalization the nerve conduction study (NCS) and the cerebrospinal fluid examination were consistent with inflammatory demyelinating polyradiculoneuropathy. While a 5-day high-dose of intravenous methylprednisolone proved to be ineffective, a single intravenous immunoglobulin cycle risulted in a significant clinical improvement without relapse after an 18-month follow-up. Based on clinical and neurophysiological findings, a diagnosis of atypical subacute GBS was finally made.</p><p>Conclusion: Although generally accepted that GBS has an acute onset within a few weeks, with a maximum of 8 weeks in the subacute variant, this case report shows that it may initially present with a very slow clinical progression and inconsistent NCS findings. However, its recognition and differentiation from the chronic inflammatory nerve disorders, which have a chronic, long-term evolution, is mandatory to provide the correct therapy protocol.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"5 ","pages":"Article 100196"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667257X23000347/pdfft?md5=bc393de806866f1835e31510e0e11ef3&pid=1-s2.0-S2667257X23000347-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139109168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0